The cardiovascular risks and benefits of quit smoking medicines
In this presentation, the speakers will report the results of a series of three population-based cohort studies relating to the use and effects of smoking cessation pharmacotherapies. The first of these studies provides evidence on how the three smoking cessation pharmacotherapies available in Australia (nicotine replacement therapy, varenicline and bupropion) compare to each other in terms of cardiovascular safety.